01 - OUR MISSION

Beyond Bispecific Antibodies

LiliumX uses protein building blocks to construct complex bispecific and multispecific biologics
Our modular approach lets us freely design drug candidates with custom modifications to create first-in-class therapeutics

Supported by

02 - ABOUT US

LiliumX Universal Assembly Platform

LiliumX uses a world-class protein conjugation technology to uncouple drug preparation from protein design. LiliumX’s Universal Assembly Platform breaks the tradeoff between combinatorial scale and drug format complexity to overcome the limits of traditional bispecific drug discovery

Sophisticated drug design and iterative discovery – a new space for unprecedented bispecifics

REACH OUT TO LEARN MORE
03 - OUR PLATFORM

Biologics
can do more

Our modular approach enables unmatched integration of binders, complex bispecific formatting, and modification – at scale
We can work with antibody fragments and other proteins – even natural ligands

Limitless modularity

We use building block protein technology that is compatible with any assets – from traditional antibodies to small peptides. LiliumX’s platform can freely integrate any biologics development

Breaking barriers

Traditional bispecific development is either scalable or flexible – not both. LiliumX’s building block approach breaks free of this restriction, enabling development of sophisticated multispecific designs with custom modifications

Target new space

LiliumX deploys a scalable pipeline for internal and collaborative discovery of bispecific antibodies, from protein design to robotic screening and AI analysis
We don’t look for ‘better’ drugs. We look for unprecedented drugs, by leveraging platform engineering, post-translational modification and in-format screening

Elevate your assets

Our Universal Assembly Platform can integrate any existing biologics asset, mixing and matching them against each other. We can repurpose biologics on our platform or test them against components in our toolbox to identify improved or novel characteristics
From multi-paratropic targeting to multi-receptor targeting. Reach out at info@liliumx.com to learn more about partnering opportunities.
04 - OUR NEWS

Latest from LiliumX

LX Graduates from YC

Learn more

OUI spins out LiliumX

Learn more

LiliumX is Hiring

Learn more